INmune Bio, Inc. (NASDAQ:INMB) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET
Company Participants
David Moss - Chief Financial Officer
Dr. RJ Tesi - Chief Executive Officer
Dr. CJ Barnum - Head of Neuroscience
Dr. Mark Lowdell - Chief Scientific Officer
Conference Call Participants
Tom Shrader - BTIG
Mayank Mamtani - B. Riley Securities
Daniel Carlson - Tailwinds Research
Operator
Greetings, and welcome to the INmune Bio Third Quarter 2022 Earnings Call. [Operator Instructions].
At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David, thank you. The floor is now yours.
David Moss
Thank you, Donna, and good afternoon, everybody. We thank you for joining us for the call for INmune Bio's Third Quarter 2022 Financial Results. With me on the call is Dr. RJ Tesi, CEO of INmune Bio; and Dr. CJ Barnum, Head of Neuroscience, who together will provide a business update on our dominant negative TNF platform, or DN-TNF for short. Also on the call is Dr. Mark Lowdell, Chief Scientific Officer of INmune Bio, who will provide an update on INKmune, our memory-like natural killer cell oncology platform.
Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor’s provision of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statements disclaimers on the company's earnings press release as well as risk factors in the company's SEC filings, including our most recent quarterly filing with the SEC. There's no assurance of any specific outcome.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
With the forward-looking statements behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of INmune Bio. RJ?
Dr. RJ Tesi
Thank you, David. And today's call is organized a little bit differently. We have both Mark Lowdell and C.J. Barnum on the call. And I believe going forward, you will see this larger cast on the calls because -- we are a complicated company with a lot of programs going on, and we believe that investors learn the most when they hear directly from the people that are responsible for those programs. So I will begin with expo with some just top line comments. And obviously, the most important issue is the clinical hold. -- that we are under from the FDA.